CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call Transcript
CBAY earnings call for the period ending September 30, 2020.
CymaBay Therapeutics Inc.
CBAY
CBAY
$5.88
$0.16
2.8%
Price as of January 22, 2021, 9:00 p.m. EST
View Interactive CBAY Charts
Interactive Chart
News & Analysis: CymaBay Therapeutics Inc.
CymaBay Therapeutics Inc. (CBAY) Q2 2020 Earnings Call Transcript
CBAY earnings call for the period ending June 30, 2020.
Here's Why CymaBay Therapeutics Rose 109% in May
The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.
Will Good News Boost This Small-Cap Drug Company's Stock Even Higher?
A do-over on one of its drugs is a potential game-changer for CymaBay.
CymaBay Therapeutics Inc (CBAY) Q1 2020 Earnings Call Transcript
CBAY earnings call for the period ending March 31, 2020.
CymaBay Therapeutics Inc (CBAY) Q4 2019 Earnings Call Transcript
CBAY earnings call for the period ending December 31, 2019.
Why Aurora Cannabis, Kirkland Lake Gold, and CymaBay Therapeutics Slumped Today
Even in a winning market, these stocks fell. Find out why.
Here's Why CymaBay Therapeutics Is Collapsing Today
The company has halted the development of its lead drug candidate in one indication and terminated two other studies involving the compound.
CymaBay Therapeutics Inc (CBAY) Q3 2019 Earnings Call Transcript
CBAY earnings call for the period ending September 30, 2019.
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
